Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ivana Sestak

Showing results (41-50 of 65) with videos related to

Pageof 7
Sort By:
Lancet (London, England)|December 17, 2019
Use of anastrozole for breast cancer prevention (IBIS-II): long-term results of a randomised controlled trialJack Cuzick, Ivana Sestak, John F Forbes, et al.
Nutrients|July 13, 2024
A Mediation Analysis of Obesity and Adiponectin Association with Postmenopausal Breast Cancer Risk: A Nested Cohort Study in the International Breast Cancer Intervention Study II (IBIS-II) Prevention TrialDebora Macis, Federica Bellerba, Valentina Aristarco, et al.
Breast Cancer Research : BCR|September 6, 2018
Novel 18-gene signature for predicting relapse in ER-positive, HER2-negative breast cancerRichard Buus, Belinda Yeo, Adam R Brentnall, et al.
The Lancet. Oncology|December 3, 2014
Changes in bone mineral density at 3 years in postmenopausal women receiving anastrozole and risedronate in the IBIS-II bone substudy: an international, double-blind, randomised, placebo-controlled trialIvana Sestak, Shalini Singh, Jack Cuzick, et al.
Journal of the National Cancer Institute|March 8, 2012
CYP2D6 and UGT2B7 genotype and risk of recurrence in tamoxifen-treated breast cancer patientsJames M Rae, Suzy Drury, Daniel F Hayes, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 22, 2014
Prediction of late distant recurrence after 5 years of endocrine treatment: a combined analysis of patients from the Austrian breast and colorectal cancer study group 8 and arimidex, tamoxifen alone or in combination randomized trials using the PAM50 risk of recurrence scoreIvana Sestak, Jack Cuzick, Mitch Dowsett, et al.
JAMA Oncology|February 17, 2018
Comparison of the Performance of 6 Prognostic Signatures for Estrogen Receptor-Positive Breast Cancer: A Secondary Analysis of a Randomized Clinical TrialIvana Sestak, Richard Buus, Jack Cuzick, et al.
Breast Cancer Research and Treatment|July 13, 2016
Relationship of ZNF423 and CTSO with breast cancer risk in two randomised tamoxifen prevention trialsAdam R Brentnall, Jack Cuzick, Helen Byers, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 21, 2020
Prognostic Value of EndoPredict in Women with Hormone Receptor-Positive, HER2-Negative Invasive Lobular Breast CancerIvana Sestak, Martin Filipits, Richard Buus, et al.
The Lancet. Oncology|December 15, 2010
Effect of tamoxifen and radiotherapy in women with locally excised ductal carcinoma in situ: long-term results from the UK/ANZ DCIS trialJack Cuzick, Ivana Sestak, Sarah E Pinder, et al.
Pageof 7

Showing results (41-50 of 65) with videos related to

Sort By:
Pageof 7
Lancet (London, England)|December 17, 2019
Use of anastrozole for breast cancer prevention (IBIS-II): long-term results of a randomised controlled trialJack Cuzick, Ivana Sestak, John F Forbes, et al.
Nutrients|July 13, 2024
A Mediation Analysis of Obesity and Adiponectin Association with Postmenopausal Breast Cancer Risk: A Nested Cohort Study in the International Breast Cancer Intervention Study II (IBIS-II) Prevention TrialDebora Macis, Federica Bellerba, Valentina Aristarco, et al.
Breast Cancer Research : BCR|September 6, 2018
Novel 18-gene signature for predicting relapse in ER-positive, HER2-negative breast cancerRichard Buus, Belinda Yeo, Adam R Brentnall, et al.
The Lancet. Oncology|December 3, 2014
Changes in bone mineral density at 3 years in postmenopausal women receiving anastrozole and risedronate in the IBIS-II bone substudy: an international, double-blind, randomised, placebo-controlled trialIvana Sestak, Shalini Singh, Jack Cuzick, et al.
Journal of the National Cancer Institute|March 8, 2012
CYP2D6 and UGT2B7 genotype and risk of recurrence in tamoxifen-treated breast cancer patientsJames M Rae, Suzy Drury, Daniel F Hayes, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 22, 2014
Prediction of late distant recurrence after 5 years of endocrine treatment: a combined analysis of patients from the Austrian breast and colorectal cancer study group 8 and arimidex, tamoxifen alone or in combination randomized trials using the PAM50 risk of recurrence scoreIvana Sestak, Jack Cuzick, Mitch Dowsett, et al.
JAMA Oncology|February 17, 2018
Comparison of the Performance of 6 Prognostic Signatures for Estrogen Receptor-Positive Breast Cancer: A Secondary Analysis of a Randomized Clinical TrialIvana Sestak, Richard Buus, Jack Cuzick, et al.
Breast Cancer Research and Treatment|July 13, 2016
Relationship of ZNF423 and CTSO with breast cancer risk in two randomised tamoxifen prevention trialsAdam R Brentnall, Jack Cuzick, Helen Byers, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 21, 2020
Prognostic Value of EndoPredict in Women with Hormone Receptor-Positive, HER2-Negative Invasive Lobular Breast CancerIvana Sestak, Martin Filipits, Richard Buus, et al.
The Lancet. Oncology|December 15, 2010
Effect of tamoxifen and radiotherapy in women with locally excised ductal carcinoma in situ: long-term results from the UK/ANZ DCIS trialJack Cuzick, Ivana Sestak, Sarah E Pinder, et al.
Pageof 7